TP53 and cancer: Importantly, knockdown of SET sensitized cancer cells to anti-neoplastic treatment with staurosporin derivative and it enhanced phosphorylation in targets regulated by p53-protein associated complex and/or targets included within the PI3K/Akt/mTOR signaling pathway [110].